Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 18/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001502 | 0.98 | MME (0.37) | MMEUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4001005 | 0.94 | TSHR (0.35) | MMETSHR | |
| SCHEMBL3999986 | 0.90 | CHRM1 (0.33) | MME | |
| SCHEMBL3994181 | 0.82 | MME (0.35) | MMEUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL13084163 | 0.80 | CHRM1 (0.52) | MME | |
| SCHEMBL3995230 | 0.80 | MME (0.35) | MME | |
| SCHEMBL3999952 | 0.79 | USP2 (0.42) | MMEUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL24548562 | 0.77 | GRM1 (0.43) | — | |
| SCHEMBL24520216 | 0.77 | GRM1 (0.43) | — | |
| SCHEMBL9360852 | 0.77 | CYP2C19 (0.45) | MMEUSP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | claimed |
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | MME 1770/4885USP2 2188/4885ALDH1A1 2020/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | MME 1734/4885USP2 2729/4885ALDH1A1 3683/4885 |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | MME 2051/4885USP2 2525/4885ALDH1A1 2064/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | MME 2041/4885USP2 2338/4885ALDH1A1 2297/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | MME 1770/4885USP2 2188/4885ALDH1A1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.